Last reviewed · How we verify
NCT01019629
Fabry Screening Study
trial in Fabry Disease in 2,724 participants. Completed in 7 December 2017.
17 April 2013
Quick facts
| Lead sponsor | Baylor Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,724 |
| Start date | 29 January 2009 |
| Primary completion | 17 April 2013 |
| Estimated completion | 7 December 2017 |
| Sites | 1 location across United States |
Conditions studied
- Fabry Disease — all drugs for Fabry Disease →
Sponsor
Baylor Research Institute
Who can join
18 and older, any sex, with Fabry Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if patients with a deficiency of alpha-galactosidase A are at-risk for cardiac complications that commonly occur in the general population
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
Schiffmann R, Forni S, Swift C, Brignol N, et al · · 2014 · cited 21× · PMID 24496231 · DOI 10.1161/jaha.113.000394 -
Low frequency of Fabry disease in patients with common heart disease.
Schiffmann R, Swift C, McNeill N, Benjamin ER, et al · · 2018 · cited 8× · PMID 29227985 · DOI 10.1038/gim.2017.175
Verify or expand the search:
- PubMed search for NCT01019629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fabry Disease
Currently open trials in the same condition.
- NCT07187440 — A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease · recruiting
- NCT06776419 — the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease · recruiting
- NCT06539624 — Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease · NA · recruiting
- NCT07277361 — Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment · recruiting
- NCT06270316 — Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease · Phase 1, PHASE2 · recruiting
Other Baylor Research Institute trials
Trials by the same sponsor.
- NCT07467720 — Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial · NA · not yet recruiting
- NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
- NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting
- NCT07096544 — CALM Study: Cardiomems Assisted Lvad Management · NA · not yet recruiting
- NCT07220395 — eHealth Literacy Intervention for Spanish Speaking Older Adults in the US · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01019629 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor Research Institute
- Last refreshed: 13 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01019629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing